SECOND AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 8th, 2019 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”), effective as of this 17th day of April, 2019 (the “Second Amendment Effective Date”), by and between Panion & BF Biotech, Inc., with offices at 16F No. 3, Yuanqu Street, Nangang District, Taipei, Taiwan, ROC (hereinafter “Licensor”), and Akebia Therapeutics, Inc., with offices at 245 First Street, Cambridge, MA as successor-in-interest to Keryx Biopharmaceuticals, Inc. (hereinafter “Licensee”).
MASTER CONSULTING SERVICES AGREEMENTMaster Consulting Services Agreement • August 8th, 2019 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Master Consulting Services Agreement, including Exhibits A-D (the “Agreement”) is entered into as of June 10, 2019 (the “Effective Date”) by and between Scott A. Canute with an address of ___________ (“Consultant”) and Akebia Therapeutics, Inc. (“Akebia” or the “Company”), a Delaware corporation having an address at 245 First Street, Cambridge, MA 02142. Consultant and Akebia are each referenced individually herein as a “Party” and together as the “Parties.”
SUPPLY AGREEMENTSupply Agreement • August 8th, 2019 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
THIS SUPPLY AGREEMENT (together with together with all Appendices, Exhibits and Schedules attached hereto, entered into by the Parties, the “Agreement”) is made and entered into on the date of last signature (the “Effective Date”) by and between AKEBIA THERAPEUTICS, INC., a Delaware corporation with an office at 245 First Street, Suite 1100, Cambridge, MA 02142 (“Akebia”) and ESTEVE QUÍMICA, S.A., a corporation organized under the laws of Spain, with an office at Torre ESTEVE – Pg. Zona Franca, 109, 08038 Barcelona, SPAIN, (“EQ”).
AMENDED AND RESTATED LICENSE AGREEMENT BY AND BETWEEN AKEBIA THERAPEUTICS, INC. AND Vifor (INTERNATIONAL) LTD.License Agreement • August 8th, 2019 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (this “Amended Agreement”) is made and entered into as of April 8, 2019 (the “Amendment Execution Date”) between Akebia Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America with its principal offices at 245 First Street, Cambridge, MA 02142 (“Akebia”), and Vifor (International) Ltd., a corporation established in accordance with Swiss laws and registered in the commercial registry under CH-107.360.718, with its premises at Rechenstrasse 37, 9014 St. Gallen, Switzerland (“Licensee”).
